Avidity Biosciences Inc

자세한 내용은 Avidity Biosciences Inc 회사

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

회사 정보

종목 코드 RNA

회사 이름Avidity Biosciences Inc

상장일Jun 12, 2020

CEOMs. Sarah Boyce

직원 수391

유형Ordinary Share

회계 연도 종료Jun 12

주소10578 Science Center Drive

도시SAN DIEGO

증권 거래소NASDAQ Global Market Consolidated

국가United States of America

우편 번호92121

전화18584017900

웹사이트https://www.aviditybiosciences.com/

종목 코드 RNA

상장일Jun 12, 2020

CEOMs. Sarah Boyce

회사 임원

이름

이름/직위

직위

주식 보유

변동

Ms. Sarah Boyce

President, Chief Executive Officer, Director

423.43K

+105.68%

Ms. Teresa Mccarthy

Chief Human Resources Officer

98.09K

+0.99%

Mr. John B. Moriarty

Chief Legal Officer, Corporate Secretary

50.00K

+100.00%

Ms. Kathleen P. Gallagher

Chief Program Officer

49.64K

-1.80%

Ms. Tamar Thompson

Independent Director

6.69K

--

Ms. Simona Skerjanec, M.D.

Independent Director

6.69K

--

Mr. Carsten Boess

Independent Director

6.69K

--

Dr. Edward M. (Ed) Kaye, M.D.

Independent Director

6.69K

--

Dr. W. Michael Flanagan, Ph.D.

Chief Scientific Officer

--

Mr. Eric B. Mosbrooker

Chief Commercial Officer

--

이름

이름/직위

직위

주식 보유

변동

Ms. Sarah Boyce

President, Chief Executive Officer, Director

423.43K

+105.68%

Ms. Teresa Mccarthy

Chief Human Resources Officer

98.09K

+0.99%

Mr. John B. Moriarty

Chief Legal Officer, Corporate Secretary

50.00K

+100.00%

Ms. Kathleen P. Gallagher

Chief Program Officer

49.64K

-1.80%

Ms. Tamar Thompson

Independent Director

6.69K

--

Ms. Simona Skerjanec, M.D.

Independent Director

6.69K

--

수익 분석

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

데이터 없음

지역별USD

이름

수익

비율

United States

1.57M

0.00%

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

Fidelity Management & Research Company LLC

12.69%

Janus Henderson Investors

9.48%

T. Rowe Price Associates, Inc.

9.30%

Wellington Management Company, LLP

8.03%

The Vanguard Group, Inc.

7.65%

Other

52.85%

주주

비율

Fidelity Management & Research Company LLC

12.69%

Janus Henderson Investors

9.48%

T. Rowe Price Associates, Inc.

9.30%

Wellington Management Company, LLP

8.03%

The Vanguard Group, Inc.

7.65%

Other

52.85%

주주 유형

주주

비율

Investment Advisor/Hedge Fund

47.08%

Investment Advisor

46.95%

Hedge Fund

6.31%

Venture Capital

5.98%

Corporation

4.21%

Research Firm

2.59%

Private Equity

1.94%

Individual Investor

1.01%

Sovereign Wealth Fund

0.60%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

495

141.64M

117.51%

-2.91M

2025Q1

508

142.16M

117.97%

-7.67M

2024Q4

492

135.01M

112.33%

-12.86M

2024Q3

467

132.62M

112.76%

+3.34M

2024Q2

414

118.94M

111.18%

+14.23M

2024Q1

365

96.48M

102.78%

+1.47M

2023Q4

345

83.09M

112.13%

-13.56M

2023Q3

334

86.17M

118.19%

-15.24M

2023Q2

328

86.81M

124.27%

-3.56M

2023Q1

328

80.46M

115.95%

-5.12M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Fidelity Management & Research Company LLC

15.29M

12.69%

-866.01K

-5.36%

Mar 31, 2025

Janus Henderson Investors

11.43M

9.48%

+4.37M

+62.01%

Mar 31, 2025

T. Rowe Price Associates, Inc.

11.21M

9.3%

+289.32K

+2.65%

Mar 31, 2025

Wellington Management Company, LLP

9.68M

8.03%

+1.58M

+19.47%

Mar 31, 2025

The Vanguard Group, Inc.

9.22M

7.65%

-188.71K

-2.01%

Mar 31, 2025

RTW Investments L.P.

8.75M

7.26%

+814.06K

+10.26%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

8.40M

6.96%

-22.20K

-0.26%

Mar 31, 2025

Avoro Capital Advisors LLC

7.63M

6.33%

+125.00K

+1.67%

Mar 31, 2025

RA Capital Management, LP

6.30M

5.23%

--

Mar 31, 2025

Bristol Myers Squibb

5.08M

4.21%

--

Sep 30, 2024

37.735USD

Avidity Biosciences Inc

37.735

개요

회사

금융